Fluorine-18-CTT 1057

Drug Profile

Fluorine-18-CTT 1057

Alternative Names: 18F-CTT1057; CTT-1057; CTT-1057-18F; CTT-1057-F-18

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Targeted Technology
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 12 Feb 2018 Advanced Accelerator Applications enters into a worldwide license agreement with Cancer Targeted Technology to develop and market Fluorine-18-CTT 1057 for the diagnosis of Prostate cancer
  • 01 Jan 2018 Phase-I clinical trials in Renal cell carcinoma (Diagnosis) in USA (IV) (NCT03427476)
  • 28 Aug 2017 Cancer Targeted Technology and University of California completes a phase I trial in Prostate cancer (Diagnosis; Metastatic disease; Late-stage disaese) in USA (IV) (NCT02916537)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top